[go: up one dir, main page]

MX2025002998A - Anticuerpos, composiciones y metodos de tratamiento - Google Patents

Anticuerpos, composiciones y metodos de tratamiento

Info

Publication number
MX2025002998A
MX2025002998A MX2025002998A MX2025002998A MX2025002998A MX 2025002998 A MX2025002998 A MX 2025002998A MX 2025002998 A MX2025002998 A MX 2025002998A MX 2025002998 A MX2025002998 A MX 2025002998A MX 2025002998 A MX2025002998 A MX 2025002998A
Authority
MX
Mexico
Prior art keywords
antibodies
treatment
compositions
methods
diseases
Prior art date
Application number
MX2025002998A
Other languages
English (en)
Inventor
Russell Rother
Original Assignee
Tetherex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetherex Pharmaceuticals Corp filed Critical Tetherex Pharmaceuticals Corp
Publication of MX2025002998A publication Critical patent/MX2025002998A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención proporciona anticuerpos anti-PSGL-1, y sus usos terapéuticos para la prevención y/o tratamiento de enfermedades. En particular, las enfermedades que se van a prevenir y/o tratar pueden ser enfermedades inflamatorias (que implican particularmente la acumulación de eosinófilos y/o neutrófilos). Los tratamientos pueden ser eficaces con respecto al asma o la EPOC. Los anticuerpos pueden estar humanizados, y pueden definirse con referencia a secuencias establecidas en la descripción. Los anticuerpos pueden tener altas afinidades para PSGL-1.
MX2025002998A 2022-09-13 2025-03-13 Anticuerpos, composiciones y metodos de tratamiento MX2025002998A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263406069P 2022-09-13 2022-09-13
US202263406545P 2022-09-14 2022-09-14
US202363452896P 2023-03-17 2023-03-17
PCT/IB2023/059093 WO2024057232A1 (en) 2022-09-13 2023-09-13 Antibodies, compositions, and methods of treatment

Publications (1)

Publication Number Publication Date
MX2025002998A true MX2025002998A (es) 2025-05-02

Family

ID=88147298

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025002998A MX2025002998A (es) 2022-09-13 2025-03-13 Anticuerpos, composiciones y metodos de tratamiento

Country Status (8)

Country Link
EP (1) EP4587056A1 (es)
JP (1) JP2025531889A (es)
KR (1) KR20250094658A (es)
CN (1) CN120265323A (es)
AU (1) AU2023343549A1 (es)
CA (1) CA3267318A1 (es)
MX (1) MX2025002998A (es)
WO (1) WO2024057232A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025191536A1 (en) * 2024-03-14 2025-09-18 Tetherex Pharmaceuticals Corporation Antibodies and methods of treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3388527A1 (en) * 2008-05-15 2018-10-17 Tetherex Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
BR112013031892A2 (pt) * 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
CN113667015B (zh) * 2021-08-20 2022-10-11 北京康特泊瑞生物医药科技股份公司 靶向psgl-1蛋白的抗体及其用途

Also Published As

Publication number Publication date
JP2025531889A (ja) 2025-09-25
AU2023343549A1 (en) 2025-03-20
CA3267318A1 (en) 2024-03-21
CN120265323A (zh) 2025-07-04
WO2024057232A1 (en) 2024-03-21
KR20250094658A (ko) 2025-06-25
EP4587056A1 (en) 2025-07-23

Similar Documents

Publication Publication Date Title
BR112021018627A2 (pt) Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
MX2025002998A (es) Anticuerpos, composiciones y metodos de tratamiento
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
MX2011013424A (es) Metodo de tratamiento del cancer con antagonista dll4 y agente quimioterapeutico.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
ZA202302158B (en) Anti-par-2 antibodies and methods of use thereof
MX2024011278A (es) Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
PH12023552792A1 (en) Combination therapies for the treatment of cancer
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
EA202190162A3 (ru) Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13
MX2024004214A (es) Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
MX2021001252A (es) Partículas de modificación inmunitaria para el tratamiento del cáncer.
HUP0301804A2 (hu) Antitrombotikus ágensek
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
MX2025001060A (es) Degradación de proteínas dirigida de parp14 para usar en terapia.
MX2025007378A (es) Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2
MX2023006704A (es) Composiciones dsg2 y metodos para el tratamiento de covid-19.
MX2022003010A (es) Tratamiento de la emr mediante cambio de terapia.
MX2024009649A (es) Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
MX2023003723A (es) Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico.